|
Resolution: standard / high Figure 2.
Results of the uncertainty analyses using a previously published transmission model
[1,2]. Blue data are predictions published previously (and described in detail in reference
1) assuming that viral attenuation in drug-resistant strains reduces only infectivity
(in comparison with drug-sensitive strains). Red data are the new predictions assuming
that viral attenuation in the drug-resistant strains reduces both infectivity and
reactivation ability. (A) The median value of the 1,000 simulations in the uncertainty analysis is plotted.
The prevalence of drug-resistant infectiousness (i.e., the prevalence of the individuals
who are shedding drug-resistant HSV-2) is shown. (B) Predictions for the Treatment Evaluation Criterion (TEC(t)) is shown; the median value
of the 1,000 simulations in the uncertainty analysis is plotted.
Gershengorn et al. BMC Infectious Diseases 2003 3:1 doi:10.1186/1471-2334-3-1 |